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Inflammation and cardiac dysfunction during 
sepsis, muscular dystrophy, and myocarditis
Introduction
Inflammation is a defending biological process to fence 
off  injurious stimuli such as pathogens, damaged tissues, 
or irritants. Temporally it can occur acutely or chronically. 
In term of the scale of  inflammation, it can occur locally 
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confined within local tissues/organs or systemically 
(whole body). Acute and/or systemic inflammation often 
accompanies with a lot of  diseases. Systemic inflammatory 
response always has noninfectious causes such as trauma and 
burns or infectious causes such as viral or bacterial infection. 
Though appropriate extent of  inflammation is protective 
and beneficial to maintain homeostasis of  the organism, 
excessive and chronic inflammation is detrimental in that 
it alters many vital organs. As we know, burn injury can 
lead to global immunological changes including suppressed 
immune function and increased susceptibility to infection.[1] 
Sepsis and septic shock are common complications in severe 
burn patients, and lead to high morbidity and mortality in 
the burn intensive care units.[2,3] In response to burn-induced 
A b s t r A c t
Inflammation plays an important role in cardiac dysfunction under different situations. Acute systemic inflammation occurring in 
patients with severe burns, trauma, and inflammatory diseases causes cardiac dysfunction, which is one of the leading causes of 
mortality in these patients. Acute sepsis decreases cardiac contractility and impairs myocardial compliance. Chronic inflammation 
such as that occurring in Duchenne muscular dystropshy and myocarditis may cause adverse cardiac remodeling including myocyte 
hypertrophy and death, fibrosis, and altered myocyte function. However, the underlying cellular and molecular mechanisms for 
inflammatory cardiomyopathy are still controversial probably due to multiple factors involved. Potential mechanisms include the 
change in circulating blood volume; a direct inhibition of myocyte contractility by cytokines (tumor necrosis factor (TNF)-a, interleukin 
(IL)-1b); abnormal nitric oxide and reactive oxygen species (ROS) signaling; mitochondrial dysfunction; abnormal excitation-contraction 
coupling; and reduced calcium sensitivity at the myofibrillar level and blunted b-adrenergic signaling. This review will summarize recent 
advances in diagnostic technology, mechanisms, and potential therapeutic strategies for inflammation-induced cardiac dysfunction.
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sepsis, cardiomyocytes release proinflammatory cytokines, 
such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b, 
IL-6,	and	nitric	oxide	(NO)	to	initiate	a	local	inflammatory	
response.[4] At the cell level, local or circulating inflammatory 
factors decrease cardiac myocyte contractility directly 
and affect the overall repair process. And in some chronic 
inflammation disease, such as diabetes, atherosclerosis, 
heart failure, and muscular dystrophy, the inflammatory 
response acts both as the reason and the result of  these 
chronic diseases and is a critical factor for the clinical 
outcomes.[5] Inflammation, especially sepsis (a severe form 
of  systemic inflammation), causes both impaired systolic 
function (cardiac depression) and diastolic function. 
Echocardiography and hemodynamic measurements often 
show reduced ejection fraction, abnormal tissue motion, and 
relaxation impairment. Electrical disturbances (arrhythmias) 
are often observed in these patients as well. Serum biomarkers 
for cardiac dysfunction such as troponin T, troponin I, and 
brain natriuretic factor (BNF) are often increased.[6,7] This 
review will summarize the clinical presentation and potential 
mechanisms of  acute and chronic inflammation induced 
cardiac contractility depression, and further address the 
advanced therapies to support cardiac recovery in sepsis-
induced cardiac dysfunction patients. 
Inflammation
Inflammation is an active biological process involving 
multiple components to clean pathogens (e.g., viruses, 
bacteria, parasites, or other invading particles such as 
allergens), injured tissue/cells (e.g., necrotic cells), 
or to respond to abnormal systemic function such as 
autoimmunity and lipoprotein deposition.[8] It intends to 
remove harmful invading pathogens or injured tissue or 
undesired molecules to restore tissue homeostasis and 
function. Inflammation can be divided into different 
forms according to the time frame of  inflammation 
development and resolution, the mechanisms of  induction, 
regulation, and resolution. Local acute inflammation is 
often manifested with redness, swelling, heat, and pain. 
Another major sign of  inflammation is the disturbance of  
tissue or organ function.[9] However, uncontrolled chronic 
inflammation is the cause for many diseases like diabetes, 
atherosclerosis, degenerative neurological diseases (e.g., 
Alzheimer’s disease), and cancer.[10] The inflammation 
process usually involves four components: the inducers, the 
sensors, the inflammatory mediators, and the target tissues. 
Inducers including pathogens, injured tissues, and other 
abnormal components in the body (e.g., monosodium urate 
crystals) can be sensed by pattern recognition receptors 
(PRRs), which are represented by Toll-like receptors (TLRs) 
and	NOD-like	 receptors.[11] Subsequently, transcription 
factors like nuclear factor kB (NF-kB) and activating 
protein 1 (AP-1) are activated in immune cells to further 
induce the production of  cytokines, chemokines, and 
antimicrobial factors.[12] As such, the inflammatory response 
is	initiated	and	maintained	till	the	stage	of 	“the	resolution	
of 	 inflammation”	when	pathogens	or	 injured	 tissues	are	
cleared. At this stage, the proinflammatory signals are 
switched to signals promoting tissue repair. However, 
for many reasons, the inducers (e.g., autoimmunity[13] 
and deposited lipoproteins) for inflammation cannot be 
cleared in a short period. Persistent presence of  inducers 
and positive reinforcement between the inducers and 
inflammation response result in chronic inflammation, 
contributing to the development of  many chronic 
inflammatory diseases such as rheumatoid arthritis, type 2 
diabetes, degenerative neurological diseases, and cancer.[14] 
Therefore, anti-inflammation has been considered effective 
therapeutics for many of  these diseases.[13]
Both acute and chronic inflammation has local or systemic 
response. In some severe infectious diseases, especially when 
the bacteria or pathogen were expanded in the vascular 
system, systemic inflammation response occurs. When 
activated immune cells, cytokines/chemokines, and tissue 
debris during acute inflammation are produced to such a scale 
that they are present in the circulation at high concentrations, 
acute inflammation becomes systemic and septic. Chronic 
inflammation happening in the vasculature, the fat tissue of  
obesity, and skeletal muscles of  muscular dystrophy is also 
systemic. Local inflammation in vital organs such as the heart 
in ischemia/reperfusion injury impairs the function of  the 
organ; systemic inflammation in sepsis may depress organ 
function remote from the inflammatory sites.
Normal cardiac function and regulation
The heart works as a pump to circulate the blood through 
the whole body, carrying necessary nutrients and oxygen 
to the peripheral tissues and removing metabolic waste 
and	CO
2
 from the tissues. Cardiac function is constantly 
regulated by the sympathetic and parasympathetic nervous 
systems (SNS and PSNS) to meet different needs of  the 
body under different physiological and pathological 
conditions.[15,16] When the adrenergic/SNS is activated, 
catecholamines are released to activate b-adrenergic 
receptors/stimulatory G protein (Gs)/adenylyl cyclase 
(AC)/cyclic adenosine monophosphate (cAMP) signaling 
pathway in cardiac myocytes, inducing chronotropic 
(increasing the heart rate), iontropic (increasing cardiac 
contractility), and lusitropic (increasing the rate of  cardiac 
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relaxation) effects. Elevated cAMP in the sinoatrial 
node (SAN) cells directly increases the funny current (I
f
) 
and activates protein kinase A (PKA) to enhance Ca2+ 
handling to accelerate the automaticity of  these cells and 
the heart rate (chronotropy).[17] The pump function of  the 
heart depends on cyclic contraction and relaxation of  the 
contractile heart cells (cardiac myocytes) in concert.
Calcium handling and excitation-contraction coupling in 
normal cardiac myocytes
Calcium (Ca2+) plays a critical role in the contraction of  
muscles including skeletal, cardiac, and smooth muscles. 
Rhythmic rise and decay of  cytosolic Ca2+ (calcium 
transient) activates myocyte contraction. The rhythm of  
calcium transients is dictated by the excitation-contraction 
coupling process: When an electrical pulse propagates from 
the SAN to the atria and ventricles, it causes depolarization 
of  cardiac myocytes by opening Na+ channels. The 
depolarization of cardiac myocytes activates the L-type Ca2+ 
channels (LTCC) causing the opening of  these channels. 
The small Ca2+ influx through the LTCC causes the release 
of  Ca2+ from the sarcoplasmic reticulum (SR) through the 
ryanodine receptor (RyR) via a Ca2+-induced Ca2+ release 
mechanism (CICR).[18,19] The binding of  Ca2+ to troponin C 
removes the inhibitory effect of  troponin I on the interaction 
between thin myofilament (actin) and thick myofilament 
(myosin) and initiates myocyte contraction. Subsequently, 
actin activates the myosin Ca2+-adenosine triphosphatase 
(ATPase) which hydrolyzes adenosine triphosphate (ATP) 
to cause the sliding of  cross-bridges between the thin (actin) 
and thick filaments (myosin) and the cell develops force and 
shortens.	This	 process	 is	 termed	“excitation-contraction	
coupling”	(EC	coupling).[20] Cytosolic Ca2+ is then removed 
by three pathways: Sequestrated back into the SR via the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), 
pumped out of  the cell via sarcolemmal Ca2+-ATPase 
and transported out of  the cell by the Na+/Ca2+ exchange 
(NCX). As the cytosolic free Ca2+ concentration decays, 
the myocyte relaxes.
This CICR process is facilitated by the special cardiac myocyte 
structure: The sarcolemmal membrane perpendicularly 
invaginates near the Z band where thin myofilaments attach 
and	forms	a	specific	subcellular	structure	termed	“transverse	
(t)	 tubule	 system”.	The	 sarcolemmal	membrane	of 	 the	
t-tubules and the membrane of  the SR in close apposition 
(junctional SR membrane) form the structure dyad. The 
critical molecules involved in CICR, the LTCC and the 
RyR, are mainly located at the t-tubules and the junctional 
SR membrane, respectively [Figure 1]. The cleft between the 
membrane of  the junctional SR and the membrane of  the 
t-tubule	is	very	narrow	(~12	nm).	On	the	longitudinal	SR	
membrane, there are phospholamban (PLB) and SERCA, 
which plays a major role in resequestrating Ca2+ back into 
the SR. The NCX is preferentially distributed within the 
t-tubules or on the membrane close to the t-tubules and 
sarcolemmal Ca2+-ATPase is evenly distributed on the 
sarcolemmal membrane.[21]
Figure 1: Scheme of cellular structures and molecules involved in excitation-contraction coupling in ventricular myocytes. The black stars indicate 
Ca2+ ions. Solid lines indicate Ca2+ influx into cytosol and dotted lines indicate Ca2+ extrusion pathways. The thickness of the line indicates the 
relative contribution of each pathway. LTCC = L-type Ca2+ channel, NCX = sodium-calcium exchanger, PLB = phospholamban, RyR = ryanodine 
receptor, SR = sarcoplasmic reticulum, SERCA = sarcoplasmic reticulum Ca2+ ATPase.
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The regulation of excitation-contraction coupling (EC) 
coupling and cardiac contractility by the  sympathetic system
As aforementioned, cardiac contractility is mainly enhanced 
by the SNS. In cardiac myocytes, cyclic AMP increased by 
released catecholamines from the SNS activates PKA by 
binding to the regulatory subunit of  PKA (PKA R) and 
relieving its inhibitory effect on the catalytic subunit of  PKA 
(PKA C). PKA phosphorylates the LTCC (the responsible 
phosphorylation sites still controversial), PLB (at Ser16) and 
RyR2 (at Ser2814) to increase the activities of  the LTCC, 
SERCA and RyR2. Consequently, the phosphorylation of  
these molecules by PKA results into a larger Ca2+ influx 
to load the SR, and a greater SR Ca2+ content, a stronger 
trigger for excitation-contraction coupling (ECC) and a 
faster, more coordinated and larger Ca2+ release from the 
SR. The greater Ca2+ release into the cytosol (a greater Ca2+ 
transient) induces stronger myocyte and cardiac contraction 
(inotropy). PKA also phosphorylates troponin I, reducing 
Ca2+ affinity of  the myofilament and thus promotes the 
dissociation of  Ca2+ from the myofilament. This effect 
of  PKA together with enhanced SERCA activity makes 
the removal of  Ca2+ from the cytosol and the relaxation 
of  the cardiac muscle faster and produces the lusitropic 
effect (lusitropy).[22] Recently, another cAMP sensor, the 
exchange protein directly activated by cAMP (EPAC), has 
been proposed to mediate the positive inotropic effect of  the 
SNS excitation via phospholipase C and Ca2+/calmodulin-
dependent protein kinase II (CaMKII).[23-27] However, the 
role of  EPAC in acute regulation of  Ca2+ handling in cardiac 
myocytes is still controversial.[28]
Cardiac dysfunction during inflammation
Diagnostic technology of monitoring cardiac function
With invasive hemodynamic measurements, it was decades 
ago several animal studies and human observations 
have demonstrated impaired left ventricular systolic and 
diastolic function in septic shock.[29,30] Researchers also 
found abnormalities and parallel alterations in the right 
ventricle.[31] Nowadays, with the development of  advanced 
diagnostic technology, the evidence of depressed myocardial 
function in sepsis patients exists not only in the abnormal 
hemodynamics, but also in some other parameters. 
Transthoracic echocardiography has become an important 
diagnostic tool for continuously monitoring cardiac function 
during hospitalization and provides real-time and direct 
information on cardiac performance rather than indirect 
implications of  clinical signs alone; radionuclide techniques 
can also provide many of these parameters but the additional 
risk of radiation exposure limits its application in the critically 
ill patients. Doppler techniques are noninvasive and simple 
to operate, but limited data can be obtained from this 
technique alone. Pulmonary artery catheter has been used 
for monitoring of myocardial performance in the critically ill 
over 20 years; however, how it should influence therapeutic 
decisions in clinic is still controversial.
Cardiac dysfunction in acute inflammation/sepsis
Sepsis has been characterized as an acute and complex 
systemic immune and inflammatory response to infections. [32] 
It usually occurs after acute and systemic injury, such as 
severe burn, trauma, and surgery, and leads to severe sepsis 
with acute organ dysfunction and septic shock (severe 
sepsis with persistent hypotension and not reversed with 
fluid resuscitation) when the host response to the global 
inflammatory response were amplified and dysregulated.[33] 
Myocardial dysfunction is present in 40% of sepsis patients 
and the mortality of  sepsis patients with cardiac dysfunction 
is up to 70%. Although sepsis-induced myocardial 
suppression is occasionally lethal, moderate sepsis induces 
cardiac	 “hibernation”	 that	 could	 be	 advantageous	 by	
preventing stress induced cardiac injury.[34-36] However, to date 
the mechanistic basis for sepsis-induced cardiac dysfunction 
is still controversial.[6,7]
In the clinic, there are two types of  sepsis-associated 
cardiovascular dysfunction according to the distinct 
hemodynamic	 characteristic:	One	 is	hyperdynamic	 state	
also called warm shock and the other is hypodynamic state 
also called cold shock. Warm shock was characterized by 
normal or high cardiac output and low systemic vascular 
resistance,[37] with which patients always have warm and 
flushed skin. Cold shock is associated with decreased cardiac 
output, hypotension, and clammy skin. Cold shock is more 
common and much more severe than warm shock. In the 
early stage of  sepsis, decreased global blood volume leads to 
low cardiac output. With aggressive fluid resuscitation and 
improvement in intravascular volume, and in combination 
of  septic shock patients’ low systemic vascular resistance, 
many patients develop a high cardiac output. 
Cardiac dysfunction in chronic inflammation caused by 
muscular dystrophy
Chronic inflammation occurring systemically or locally in 
the heart also has significant impact on cardiac function 
through many mechanisms. As the underlying causes of  
inflammation in chronic inflammation are different from 
those of  acute inflammation, the underlying mechanisms 
for cardiac dysfunction by chronic inflammation include 
some distinct signaling pathways. We will use cardiac 
dysfunction induced by the chronic inflammation condition 
occurring in muscular dystrophy as an example here.
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Duchenne muscular dystrophy (DMD) is a rare inherited, 
X-linked recessive disease affecting the function of  skeletal 
and cardiac muscles in 1 out of  3,600-6,000 live newborn 
males.[38] DMD patients have very poor quality of  life and 
prognosis.[38] It leads to muscular dystrophy and eventually 
death in the young males. The early manifestation of  this 
disease is the weakness in skeletal muscles and the loss of  
mobility due to the degeneration of  skeletal muscles.[39] 
Weakening of  the diaphragm results in the death of  DMD 
patient due to respiratory failure. However, now with 
ventilation support, DMD patients can survive longer than a 
decade ago.[39] Thus more DMD patients are surviving with 
cardiac dysfunction and eventually dilated cardiomyopathy.[39] 
Cardiac dysfunction at rest is detected at the age of early teens 
or even at the age of  8-9 years with three-dimensional (3D) 
strain, torsion, and dispersion analyses.[40-44]
Cardiac dysfunction in DMD has long been recognized with 
initial pathology including myocyte hypertrophy, myocardial 
fibrosis, typical electrocardiographic abnormalities, and 
abnormal wall motion detected by early echocardiography. 
Cardiomyopathy in DMD generally starts as a preclinical 
or intermediate stage, with symptoms and signs of  heart 
failure such as dyspnea, peripheral edema, and liver 
enlargement. However, in few patients the dilation could 
be the first manifestation of  the heart involvement, caused 
by a diffusing disorganized fibrosis. The ability to detect 
overt cardiomyopathy increases with age, so that more 
than 80% of  boys older than 18 years will have abnormal 
systolic function.[45]
Though it is believed that cardiac myocyte death is due to 
the loss of membrane integrity, Ca2+	overload	and	NO	over	
production is the major contributor to cardiac dysfunction 
in DMD patients,[46,47] the underlying mechanisms for the 
development of dilated cardiomyopathy in DMD patients 
is still not entirely clear. Massive death of myocytes in the 
skeletal and cardiac muscles results in intense inflammation[48] 
and prostaglandin E2 (PGE2) production in DMD 
patients.[49,50] The role of systemic inflammation and local 
cardiac inflammation in cardiac dysfunction in DMD is 
still unclear. As we have recently shown, PGE2 is able to 
inhibit acute a-adrenergic response via a phosphodiesterase-
coordinated local cAMP regulation.[51] We have also observed 
that there is a blunted cardiac a-adrenergic response of the 
heart of the mdx mouse, a mouse model of human DMD.
Cardiac dysfunction with initial acute inflammation 
followed by chronic inflammation
Some events such as myocarditis lead to acute inflammation 
then followed by chronic inflammation. Myocarditis is 
an inflammation of  cardiac muscle caused by infectious 
(bacterial, viral, and fungal) and noninfectious (autoimmune, 
toxic, drug-induced hypersensitive, and vasculitic) insults 
that first induce an acute inflammation, and then chronic 
inflammation if  the pathogens cannot be completely 
removed.[52] The incidence of  myocarditis is not exactly 
known, but it accounts for 9.6% of  unexplained heart 
failure and 12% of  sudden death of  patients younger than 
40.[53] Approximately 21% patients having acute myocarditis 
develop dilated myopathy.[54] The 5-year survival rate of  
biopsy-proven myocarditis is about 50%. Virus infection 
is the most often cause of  myocarditis.[52] During past 20 
years, there is a shift of  the virus causing myocarditis: In 
the middle and late 1990s, enterovirus especially coxsackie 
B virus, was the main cause of  viral myocarditis; then 
adenoviruses were found as the major virus; in recent 
years, parvovirus B19 was found to be the major virus.[52] 
Myocarditis can be divided into three phases: Initial viral 
infection activating innate immune response by lysing 
cardiomyocytes and activating antigen-presenting cells; 
usually viruses are cleaned during the first phase without 
much damage to the heart. However, if  viruses are not 
cleaned, the second phase with adaptive immune response is 
ensued. The adaptive immune response is more specific with 
T-cells and antibodies against some cardiac proteins such 
as myosin and a-adrenergic receptor. In most patients, the 
viruses are cleaned after that but few patients may advance 
into	 the	chronic	“inflammatory	cardiomyopathy”	phase,	
which causes diastolic cardiomyopathy with depressed 
cardiac function.[52]
Most myocarditis patients recover after the initial phase 
without any clinical cardiac dysfunction. However, in 
some patients with myocarditis, acute inflammation 
could cause acute heart failure, arrhythmias, and sudden 
cardiac death.[52,55] A study by the European Study of  the 
Epidemiology and Treatment of  Cardiac Inflammatory 
Disease (ESETCID) found that 72% of myocarditis patients 
had dyspnea, 32% had chest pain and 18% had arrhythmias.[55] 
Physical examinations could find tachycardia, soft S1 sounds 
and S3 and S4 gallop, nonspecific ST-T wave changes, 
atrioventricular block, and intraventricular block.[56] In some 
patients, there are acute infarction like symptoms.
Mechanisms for cardiac dysfunction 
induced by inflammation
Mechanisms for cardiac dysfunction during sepsis
Reversible myocardial depression is common in human 
septic shock. In most septic shock patients, ventricular 
dysfunction was evident at admission. Hemodynamic or 
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metabolic	 changes	and	autonomic	dysfunction,	and	NO	
and a derangement in catecholaminergic stimulation.[7,61] 
Endothelial dysfunction with consequent microcirculatory 
and mitochondrial dysfunction, and circulating factors are 
considered to be the most important mechanisms of  acute 
inflammation induced myocardial dysfunction[62] [Figure 2].
Cytokines act as the most important mediators of  the 
inflammatory process. TNF-a and IL-1b are postulated 
to play a key pathophysiologic role during sepsis. Serum 
levels of  TNF-a and IL-1b are increased during an 
inflammatory response, imposing a negative inotropic 
effect on cardiomyocyte contractility.[63,64] Circulating IL-
6, IL-8, and IL-10 are potent cardiomyocyte contractility 
depressor.[65] Some in vitro studies have shown that the 
depression of  cardiomyocyte contractility induced by septic 
serum is not directly dependent on elevated levels of  TNF-a 
and IL-1b, but Duncan et al. revealed that TNF-a and IL-
1b increase the SR Ca2+ leak from the SR, contributing to 
the depressed Ca2+ transient and contractility. [66] Maass 
and coworkers found that burn injury or burn serum 
pretreatments increases cardiomyocyte cytosolic and 
mitochondrial Ca2+ and promotes myocyte secretion of  
TNF-a, IL-1b, and IL-6, which induce mitochondrial injury 
of  cardiomyocytes during sepsis and burn trauma.[67] The 
circulating	levels	of 	thrombopoietin	(TPO)	is	increased	by	as	
much as two-folds than in the healthy person accompanied 
by increased monocyte-platelet aggregation (i.e., P-selectin 
expression) in burn patients with sepsis.[68] Much has been 
done to verify the important role of  TLR4 as a mediator of  
septic shock and myocardial infarction (MI)-induced cardiac 
echocardiography examination always show ventricular 
dilatation and decreased left ventricular ejection fraction 
(LVEF), and these abnormalities were more pronounced 
in survivors than in nonsurvivors. At the same time, 
survivors have better response with hemodynamic support 
during the monitoring period.[57] However, the latest meta-
analysis did not show lower ejection fractions in survivors 
than nonsurvivors of  severe sepsis or septic shock.[58] Early 
understanding of  cardiac dysfunction in sepsis was based 
on the hypothesis of  global myocardial ischemia, but 
later studies in animal and human showed high coronary 
blood flow and decreased myocardial oxygen utilization in 
sepsis.[59] Furthermore, studies found no significant changes 
at the organ, cellular, and molecular levels of  depressed 
hearts of  septic patients. Takasu et al., found myocyte death 
is rare in sepsis induced cardiac dysfunction patients.[60] 
All the evidence supports that sepsis-induced myocardial 
dysfunction is an acute and reversible response and much 
more like a self-protection response in emergency, so 
functional changes rather than anatomical abnormalities 
is the underlying pathophysiology. However, cardiac 
dysfunction in sepsis is multifactorial and involves multiple 
and complex pathways.
As mentioned above, most evidence showed acute cardiac 
dysfunction induced by septic stress is reversible in survivors 
within 7-10 days, supporting that the pathophysiology basis 
is functional rather than structural. The mechanisms of  
myocardial dysfunction are related to inflammatory response 
mediated by cytokines, oxidative stress and mitochondrial 
abnormalities, alterations of  micro- and macrocirculation, 
Figure 2: Mechanisms for cardiac dysfunction induced by inflammation.
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dysfunction in the acute phase as well.[4] Besides classical 
cytokines, some new inflammation mediators (IL-7, IL-
17A, IL-22, and IL-33), soluble receptor sTREM-1, stress 
mediators HMGB1, histones glycoprotein osteoponitin, lipid 
mediators (S1P and RvD2), resistin adipokines (adiponectin 
and visfatin), vasoactive peptides (ghrelin, AM/AMBP-1, 
and ET-1), and growth factor (MFC-E8) were verified to 
participate in the inflammatory response during sepsis.[69] 
However, the roles of  these mediators in cardiac dysfunction 
during sepsis have not been studied.
NO	not	only	plays	an	important	role	in	the	development	of 	
sepsis induced cardiac dysfunction, but also has protective 
effects. Chronic stress and inflammation have dysfunctional 
NO	signaling	 and	 insulin	 resistance	which	 affect	many	
tissues, including the vasculature, the myocardium, and 
the musculature.[70] The ensuing vascular dysfunction and 




) leads to systemic hypotension and myocardial 
dysfunction	associated	with	 sepsis.	The	 increases	 in	NO	
production during sepsis can increase S-nitrosylation of  
proteins that may lead to cardiac dysfunction. Sips et al., 
found that increasing S-nitrosoglutathione reductase 
(GSNOR),	an	enzyme	promoting	denitrosylation	activity,	can	
improve myocardial dysfunction during sepsis by reducing 
protein S-nitrosylation during sepsis and thus increasing 
cardiac myofilament sensitivity to Ca2+.[71] However, clinical 
trials	using	nonselective	NOS	inhibitors	showed	increased	
mortality in septic patients, suggesting a protective role of  
nitric	oxide	synthase	1	(neuronal	NOS)	(NOS1)	and/or	nitric	
oxide	 synthase	3	 (endothelial	NOS)	 (NOS3)	 in	 sepsis.[72] 
Cardiomyocyte-specific	NOS3	overexpression	mice	having	
increased	myocardial	NO	 levels	 can	attenuate	endotoxin-
induced	 reactive	 oxygen	 species	 (ROS)	 production	 and	
increase total SR Ca2+ load and myofilament sensitivity to 
Ca2+, thereby reducing cardiac depression (reduced cardiac 
contractility) in septic shock mice.[72] It seems that local 
NO	production	combined	with	cytokine	release	plays	a	key	
pathophysiological role during early stage of  sepsis.[73]
Mitochondrial derangement plays a key role in the 
mitochondrial bioenergetic dysfunction in tissue injury and 
sepsis-associated multiorgan failure.[74] Cell death is rare 
in sepsis-induced cardiac dysfunction, but sepsis-induced 
focal mitochondrial injury occurs. Though till now there 
is no direct evidence to prove the relationship between the 
morphologic change of  mitochondria and cardiomyocyte 
function depression, the mitochondrial swelling of the septic 
cardiomyocyte is relevant to sepsis-induced myocardial 
depression.[60] Zang et al., demonstrated that sepsis leads 
to	mitochondria	membrane	damage	to	increase	ROS	and	
change	the	defense	capability	to	ROS;[75] they also found that 
inhibiting	of	mitochondrial	ROS	by	a	mitochondria-targeted	
vitamin E in a sepsis animal model can protect mitochondrial 
function and attenuate tissue-level inflammation to improve 
cardiac function during sepsis.[76]
Altered myofilament Ca2+ sensitivity, abnormal calcium 
homeostasis, and defects in cardiomyocyte coupling by gap 
junctions have also been proposed as potential causes of  
sepsis-induced cardiac depression though it is still unclear 
which is the major cause. Many studies have shown reduced 
Ca2+ sensitivity of  the myofilament of  cardiomyocytes 
during sepsis.[77,78] The reduced myofilament Ca2+ sensitivity 
is more related to the changes of  the regulatory proteins 
(tropomyosin and troponin) rather than the changes of  
the structural myofilament proteins (actin and myosin) 
because the maximal Ca2+-activated tension tends to 
be unchanged.[77,79] Levosimendan, a troponin-C Ca2+-
sensitizer, markedly enhanced left ventricular function in 
animals with experimental septic shock,[80] but Behrends 
and Peters[81] reported reduced Ca2+ sensitivity during 
sepsis was not due to troponin-C, but probably increased 
troponin-I phosphorylation.[79] There are also reports 
showing that critical molecules involved in Ca2+ handling 
including the L-type Ca2+ channel,[82] the Ca2+ release 
channel RyR2[83] and SERCA,[84] are reduced during sepsis, 
contributing to reduced cardiac myocyte contractility. Also, 
the phosphorylation of  phospholamban could be decreased, 
enhancing the inhibitory effect of  PLB on SERCA and 
reducing Ca2+ uptake into the SR.[85] The potential increased 
Ca2+ leak from the SR through RyR may decrease SR 
Ca2+ content and increase diastolic Ca2+ to cause both 
systolic and diastolic cardiac dysfunction.[86] However, the 
molecular signaling involved in inflammation-regulated 
Ca2+ handling needs to be further defined.
An underlying mechanism for cardiac depression after 
acute or chronic inflammation is that excess activation 
of  the SNS leads to adverse cardiac remodeling and a 
blunted adrenergic response. But how the cytokines or 
inflammation signal affects b-adrenergic signal is not 
clear. PGE2 is found to be elevated quickly after burn 
or in sepsis.[87] We recently found that PGE2 stimulation 
can attenuate the adrenergic-induced cardiac contractile 
response in animal hearts and cardiac myocytes via 
activating phosphodiesterase 4Ds (PDE4Ds), a novel 
mechanism might contribute to reduced b-adrenergic 
reserve of  the heart,[51] but also provide cardioprotection 
against b-adrenergic overactivation.
During chronic inflammation, the cytokines, chemokine, 
NO,	ROS,	and	altered	Ca2+ handling could have similar 
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effects as they exert during acute inflammation but in 
general, local concentrations of  these factors may be 
low. However, prolonged presence of  these factors at 
low concentrations induces adverse cardiac remodeling 
via promoting myocyte hypertrophy and apoptosis, the 
differentiation of  fibroblast into myofibroblasts and 
extracellular matrix protein production (fibrosis).[88] 
Myocardium fibrosis impairs cardiac diastolic function. 
Both Ca2+	 and	NO	 in	 cardiac	 and	 respiratory	muscle	
pathways have been shown to be important to the etiology 
of  DMD. In DMD, the preservation of  relatively normal 
calcium reuptake and diastolic/systolic sheet mechanics 
throughout the rest of  the heart, together with the rapid 
reversibility of  functional defects by reducing cytosolic 
calcium, points to the significance of  regional mechanical 
factors in the progression of  the disease.[89] Interestingly, 
some inflammatory factors in chronic inflammation can 
be both detrimental and beneficial. For example, while 
TLR4 initiates inflammation, it might also protect the 
myocardium.[90] The activation of  TLRs leads to nuclear 
translocation of  NF-kB to induce the production of  
cytokines and adhesion molecules in immune cells and 
nonimmune cells such as endothelial cells, fibroblasts, 
and cardiomyocytes. These cytokines plays critical roles 
in myocarditis and cardiomyopathy.[91] Protease activated 
receptor 1 and 2 (PAR1 and PAR2),[92] IL-1b,[93] IL-6,[94] and 
IL-18[95] also stimulate cardiomyocyte hypertrophy. IL-18 
may be proapoptotic and prohypertrophic as well.[95]
In summary, the mechanisms for cardiac dysfunction 
induced by inflammation have not been fully understood 
and it seems that multiple underlying mechanisms 
for cardiac dysfunction for both acute and chronic 
inflammation are overlapping. There could be difference 
in the relative contribution to each inflammatory condition 
and to different stages of  inflammation.
Treatments
General considerations for treating cardiac dysfunction 
during inflammation
The guidelines for management of  severe sepsis and septic 
shock[33] provide details about the grading and evaluation 
system, and different treatments for different stage of  
sepsis and septic shock. The guidelines also emphasize 
the importance that acute management of  sepsis and 
septic shock is the foundation of  improved outcomes for 
this group of  critically ill patients. The basic principle for 
treating diseases is early diagnosis for early treatment, so 
is the same for sepsis induced myocardial dysfunction. 
Early detection of  sepsis induced myocardial injury is 
based on the biomarkers and noninvasive diagnostic 
methods. Cardiac troponins are regulatory proteins of  the 
cardiac muscle, and they are highly sensitive and specific 
markers of  myocardial damage. Cardiac troponin I (cTnI) 
and cardiac troponin T (cTnT) are released as a result 
of  myocardial cell injury though they are also elevated 
in some other acute diseases, such as acute coronary 
syndrome, acute kidney injury, and pulmonary embolism. 
High troponin or brain natriuretic peptide (BNP) levels 
are associated with myocardial dysfunction and a higher 
mortality.[96] In Lupia et al.’s study, they found increased 
circulating	 levels	of 	TPO	after	burn	 injury,	as	much	as	
two-fold of  that in the healthy. Additionally, they also 
found increased monocyte platelet aggregation in burn 
patients with sepsis, which can be a potential indicator 
for developing sepsis, microvascular dysfunction, and 
multiorgan failure.[68] Myocardial function is depressed in 
sepsis and is an important prognosticator in the critically ill 
patients. The degree and recovery time of  sepsis-induced 
cardiac dysfunction is determined by the severity of  sepsis, 
but cardiac dysfunction can be reversible in most survivors. 
In animal studies, it was found that the amount of  
transcripts of  genes related to the TLR2/MyD88 (TLR 2/
myeloid differentiation factor 88) and JAK/STAT (Janus 
kinase/signal transducer and activator of  transcription) 
inflammatory pathways, b-adrenergic signaling, and 
intracellular calcium cycling was significantly correlated 
with the extent of  cardiac dysfunction.[97]
As for treatment, there is no specific treatment for 
sepsis induced myocardial dysfunction. Current general 
therapeutic strategies include controlling infection, 
hemodynamic support, modulation of  the host response 
and critical care support.[74] Although a lot of  evidence 
speculates that stress induced myocardial dysfunction as 
a temporary compensatory mechanism advantageous for 
patients, but septic shock patients still require the use of  
inotropic agents and/or vasopressors to maintain adequate 
mean arterial pressure, oxygen delivery, and myocardial 
contractility.[60] It also requires an adequate systemic fluid 
support to maintain perfusion pressures and sufficient blood 
flow for regional and global demands.
To treat chronic inflammation induced cardiac dysfunction 
such as the one happening in DMD patients, anitimmune 
therapy has not been successful yet[98] and cardioprotective 
therapy is used to ameliorate cardiac remodeling and 
dysfunction. While efforts continue toward optimizing cardiac 
and respiratory care for DMD patients, there is no cure for 
this disease and treatment is limited to glucocorticoids to 
prolong ambulation and drugs to treat the cardiomyopathy.[98] 
The treatments used for the DMD cardiomyopathy are based 
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on the weakness of cardiac function. Supportive approaches 
for ventilation and circulation can be used to improve the 
quality of  life and natural history of  DMD patients.[99] 
Plasma cytokines during chronic inflammation and acute-
phase reactants, including TNFa, IL-6, C-reactive protein, 
and fibrinogen, can be monitored in DMD to follow-up the 
progression of the disease.[100]
Cardioprotective therapy
As aforementioned, despite treating the primary diseases, 
cardioprotective therapies for acute or chronic inflammation 
induced myocardial dysfunction are important. In sepsis or 
DMD patients, b-blockers as a classic drug to treat cardiac 
diseases are not only having the effects of preventing ischemia, 
decreasing oxygen demand, and TNF production[7]; they 
also reduce local and systemic inflammation.[101] Cardiac 
inotropy can be increased by levosimendan, istaroxime, 
or omecamtiv mecarbil without greatly increasing cellular 
oxygen demands. Heart rate reduction with ivabradine 
reduces myocardial oxygen expenditure and ameliorates 
diastolic filling. Immunomodulation and nutrition support 
are also important to protect cardiac function because 
stress and inflammation are catabolic processes. All these 
treatments can be used preventively.
b-adrenergic blockade and angiotensin II receptor blockade
The benefits of  b-blockade have been demonstrated in 
clinical trials of  pediatric severe burn, heart failure, severe 
trauma, and traumatic brain injury.[7] As b-adrenergic stress 
is a major factor in sepsis-induced myocardial dysfunction, 
the use of  b-blocking agents could be beneficial. However, 
this is still controversial as it may have potential negative 
inotropic effect in patients with sepsis induced myocardial 
dysfunction. There are several experimental studies using 
b-blockers in sepsis, showing mortality reduction if  
commenced before a septic insult.[7] In an animal model 
with sepsis, b-blocker showed promising effect on reducing 
heart rate, maintaining cardiac stroke volume, and reducing 
inflammation and the organ injury.[102-104] In burned children, 
treatment with propranolol (a nonselective b-blocker) 
during hospitalization attenuates hypermetabolism 
and reverses muscle-protein catabolism.[105] Preexisting 
b-blockers treatment has the potential to improve adult burn 
outcomes as well.[106] However, post injury treatment needs 
to be further studied in randomized clinical trials too. Study 
with two rat models, adjuvant arthritis and subcutaneous 
air pouch edema, showed antiarthritic effects by carvedilol. 
Carvedilol, a a1-, b1-, and b2-adrenergic receptor blocker 
that	 can	 increase	 eNOS	activity,[70] attenuated leukocyte 
migration, oxidative stress response, and the production 
of  proinflammatory cytokines (TNF-a and IL-6) and 
eicosanoids (PGE2 and LTB4).[107] Besides traditional 
inhibition of  AT1 to AT2 receptors, angiotensinogen 
converting enzyme (ACE) inhibitors also have positive 
effects on chronic inflammation in atherosclerosis. Though 
they cannot reverse cardiac remodeling, they can reduce 
acute cardiovascular events during inflammation.[108-110] 
Angiotensin receptor blockers (ARBs) have the similar 
clinical effects as ACE inhibitors though they work through 
different	mechanisms,	 like	 increasing	NO	bioavailability	
and improving insulin sensitivity.[70]
Levosimendan
Levosimendan is a new pharmacological agent used in the 
management and treatment of acute and chronic heart failure. 
Unlike other inotropic agents, as a myofilament calcium 
sensitizer, it can improve cardiac performance without 
activating the SNS and changing oxygen consumption. 
Levosimendan binds to the N-terminal of  troponin C 
with high affinity at high [Ca2+]
i
 that can only be reached 
during systole, prolonging the interaction of  myosin and 
actin filaments through the inhibition of  troponin I.[111] 
Levosimendan have been applied in some observational 
studies, such as a perioperative use, cardiogenic shock, 
sepsis, and right ventricular dysfunction.[112] Levosimendan 
has vasodilatory and cardioprotective effects mediated by 
opening ATP-dependent K+ channels and mitochondrial 
ATP-sensitive potassium (mito.K(ATP)) channels in 
cardiac myocytes and vascular smooth muscle cells.[113] This 
inotropic agent also has mild PDE inhibitory action.[114] 
Moreover, there is evidence that levosimendan has additional 
anti-inflammatory effect in the prevention or treatment of  
acute or chronic inflammation depending on the pathogenic 
factor.[115] Doorduin and coworkers[116] found levosimendans 
improve contractile function of  the diaphragm in the 
acquired diaphragm muscle weakness patients. However, 
there is no related report using levosimendan to treat DMD 
that can potentially be treated with this drug.
Ivabradine





 is important for 
generating the pacemaking current, and responding to 
b-adrenergic stimulation of  the SAN cells. The (I
f
) blocker 
ivabradine reduces heart rate and improves systolic function 
without causing apparent direct hemodynamic effects. 
Contrary to b-blockers, ivabradine has no hypotensive 
character. When body suffers stress including sepsis, 
burn, and trauma; the heart rate is accelerated causing 
tachycardia.[117,118] Lots of studies have demonstrated that the 
heart rate is a major independent cardiovascular risk factor 
for adverse prognosis.[119] Reduction of  heart rate is the main 
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effect of  ivabradine and protects the myocardium against 
ventricular dysfunction induced by tachycardia. These effects 
can improve endothelial function, modulate immune cells 
and enhance a long-term adaptation in calcium handling.[120] 
In a dystrophy case report, ivabradine normalizes sinus 
tachycardia and heart failure in Becker’s muscular 
dystrophy patients with dilated cardiomyopathy and reduces 
arrhythmic events and left ventricular remodeling.[121]
Prospect
Both acute (e.g., sepsis and acute myocarditis) and chronic 
inflammation (e.g., muscular dystrophy) can cause cardiac 
dysfunction, which is an often cause of  mortality and 
morbidity in medical conditions causing inflammation. 
However, inflammation may also exert protection on the 
heart. Many mechanisms including signaling pathways 
involving	 cytokines	 and	 chemokines,	NO,	and	Ca2+ and 
b-adrenergic system are underlying both the detrimental 
and salutary effects of  inflammation. Anti-inflammatory 
clinical trials have not succeeded thus far. Current treatments 
for cardiac dysfunction after inflammation focus on 
cardiovascular support, limiting cardiac injury and adverse 
remodeling with inhibition of  b-adrenergic and the renin-
angiotensin-aldosterone system (RAAS) systems, and 
reducing heart rate. A better understanding of the underlying 
mechanisms for both detrimental and protective effects 
of  inflammation under different conditions in the heart is 
needed for future development of effective therapy to prevent 
cardiac injury caused by inflammation while at the same time 
to preserve necessary and protective aspects of inflammation.
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